Fair Value, Hierarchy [Axis] Fair Value, Inputs, Level 1 [Member] Fair Value, Inputs, Level 2 [Member] Fair Value, Inputs, Level 3 [Member] Equity Components [Axis] Common Stock [Member] Option Indexed to Issuer's Equity [Axis] Employee Stock Option [Member] Award Type [Axis] Restricted Stock [Member] Short-term Debt, Type [Axis] Convertible Notes Payable [Member] Placement Agency Agreement [Axis] Lfb Group [Member] Additional Paid-in Capital [Member] Treasury Stock [Member] Accumulated Deficit [Member] Contingently Issuable Share [Member] Cash and Cash Equivalents [Axis] Convertible Notes [Member] Income Tax Authority [Axis] Us Federal Income Tax [Member] Legal Entity [Axis] Opus [Member] Contractual obligations [Axis] Contractual obligations [Member] Schedule of Fair Value of Separate Accounts by Major Category of Investment [Axis] Short-term Investments [Member] Major Types of Debt and Equity Securities [Axis] US Government Agencies Debt Securities [Member] Warrants [Member] Shares Upon Note Conversion [Member] JBET Agreement [Member] Shared Services Agreement [Member] Agreement Type [Axis] Atm [Member] ATM [Member] Non Employee Restricted Stock Type Of Transaction [Axis] Manhattan and Ariston Pharmaceuticals Merger [Member] Indefinite-lived Intangible Assets [Axis] Licensing Agreements [Member] Licensing Agreements IRAK4[Member] Document And Entity Information [Abstract] Document Type Amendment Flag Document Period End Date Document Fiscal Year Focus Document Fiscal Period Focus Entity Registrant Name Entity Central Index Key Current Fiscal Year End Date Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Filer Category Entity Common Stock, Shares Outstanding Entity Public Float Trading Symbol Statement of Financial Position [Abstract] Assets Current assets: Cash and cash equivalents Short-term investment securities Interest receivable Prepaid research and development Other current assets Total current assets Restricted cash Leasehold interest, net Equipment, net Goodwill Other assets Total assets Liabilities and stockholders' equity Current liabilities: Accounts payable and accrued expenses Accrued compensation Current portion of deferred revenue Notes payable Total current liabilities Deferred rent Deferred revenue, net of current portion Total liabilities Commitments and contingencies Stockholders' equity: Preferred stock, $0.001 par value per share (10,000,000 shares authorized, none issued and outstanding as of December 31, 2017 and 2016) Common stock, $0.001 par value per share (150,000,000 shares authorized, 73,181,750 and 56,820,422 shares issued, 73,140,441 and 56,779,113 shares outstanding at December 31, 2017 and 2016, respectively) Additional paid-in capital Treasury stock, at cost, 41,309 shares at December 31, 2016 and 2015 Accumulated deficit Total stockholders' equity Total liabilities and stockholders' equity Preferred stock, par value (in dollars per share) Preferred stock, shares authorized Preferred stock, shares issued Preferred stock, shares outstanding Common stock, par value (in dollars per share) Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Treasury stock, shares Income Statement [Abstract] License revenue Costs and expenses: Research and development: Noncash compensation Other research and development Total research and development General and administrative: Noncash compensation Other general and administrative Total general and administrative Total costs and expenses Operating loss Other (income) expense: Interest income Other (income) expense Total other income, net Net loss Basic and diluted net loss per common share (in dollars per share) Weighted average shares used in computing basic and diluted net loss per common share (in shares) Statement [Table] Statement [Line Items] Compensation [Axis] Balance Balance (in shares) Issuance of common stock in connection with exercise of warrants Issuance of common stock in connection with exercise of warrants (in shares) Issuance of common stock in connection with cashless exercise of warrants Issuance of common stock in connection with cashless exercise of warrants (in shares) Issuance of common stock in connection with conversion of notes payable Issuance of common stock in connection with conversion of notes payable (in shares) Issuance of restricted stock Issuance of restricted stock (in shares) Forfeiture of restricted stock Forfeiture of restricted stock (in shares) Issuance of common stock to related party for cash (See Note 9) Issuance of common stock to related party for cash (See Note 9) (in shares) Issuance of common stock in At-the-Market offering (net of offering costs) Issuance of common stock in At-the-Market offering (net of offering costs) (in shares) Compensation in respect of restricted stock granted to employees, directors and consultants Issuance of common stock in At the Market offering Issuance of common stock in At the Market offering (in shares) Adjustment to contingently issuable shares Net loss Balance Balance (in shares) Statement of Cash Flows [Abstract] CASH FLOWS FROM OPERATING ACTIVITIES Consolidated net loss Adjustments to reconcile consolidated net loss to net cash used in operating activities: Gain on sale of long-term securities Noncash stock compensation expense Depreciation Amortization of premium on investment securities Change in fair value of notes payable and accrued interest Changes in assets and liabilities: Increase in restricted cash Decrease (increase) in other current assets Decrease (increase) in leasehold interest (Increase) decrease in accrued interest receivable Decrease (increase) in other assets Increase (decrease) in accounts payable and accrued expenses Increase in deferred rent Decrease in deferred revenue Net cash used in operating activities CASH FLOWS FROM INVESTING ACTIVITIES Purchases of equipment Investment in held-to-maturity securities Proceeds from maturity of short-term securities Proceeds from the sale of long-term securities Net cash provided by (used in) investing activities CASH FLOWS FROM FINANCING ACTIVITIES Proceeds from the exercise of warrants Proceeds from sale of common stock, net Deferred financing costs paid Net cash provided by financing activities NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS Cash and cash equivalents at beginning of year CASH AND CASH EQUIVALENTS AT END OF YEAR NONCASH TRANSACTIONS Reclassification of deferred financing costs to additional paid-in capital Conversion of convertible notes payable to common stock Accounting Policies [Abstract] ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Cash and Cash Equivalents [Abstract] CASH AND CASH EQUIVALENTS Investments, Debt and Equity Securities [Abstract] INVESTMENT SECURITIES Fair Value Disclosures [Abstract] FAIR VALUE MEASUREMENTS Stockholders' Equity Note [Abstract] STOCKHOLDERS' EQUITY Debt Disclosure [Abstract] NOTES PAYABLE Income Tax Disclosure [Abstract] INCOME TAXES License Agreement [Abstract] LICENSE AGREEMENTS Related Party Transactions [Abstract] RELATED PARTY TRANSACTIONS Commitments and Contingencies Disclosure [Abstract] COMMITMENTS AND CONTINGENCIES Disclosure Text Block [Abstract] QUARTERLY FINANCIAL INFORMATION Litigation LITIGATION Subsequent Events [Abstract] SUBSEQUENT EVENTS Description of Business Liquidity and Capital Resources Recently Issued Accounting Standards Use of Estimates Cash and Cash Equivalents Cash and Cash Equivalents, Restricted Cash and Cash Equivalents Investment Securities Credit Risk Revenue Recognition Research and Development Costs Income Taxes Stock-Based Compensation Basic and Diluted Net Loss Per Share Common Share Long-Lived Assets and Goodwill Organization And Summary Of Significant Accounting Policies Tables Dilutive securities excluded from computation Schedule of Cash and Cash Equivalents Held-to-maturity Securities Fair Value, Liabilities Measured on Recurring and Nonrecurring Basis Change In Level Three Fair Value During Period Schedule of Share-based Compensation, Stock Options, Activity Schedule of Nonvested Restricted Stock Units Activity Schedule Of Warrants Activity Schedule Of Share Based Compensation Expense Schedule of Debt Schedule of Deferred Tax Assets and Liabilities Schedule of Effective Income Tax Rate Reconciliation Schedule of Loss Contingencies by Contingency Table Text Block Supplement [Abstract] Schedule of Quarterly Financial Information Options [Member] Antidilutive securities excluded from computation of diluted loss per share Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Period Anticipated Sufficient To Fund Operating Cash Flow Restricted Cash and Investments Prepaid Manufacturing Money market funds Checking and bank deposits Total Stock Issued During Period Share Issued For Cash [Axis] Amortized cost, as adjusted Gross unrealized holding gains Gross unrealized holding losses Estimated fair value Fair Value, by Balance Sheet Grouping [Table] Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] 5% Notes Totals Balance at January Interest accrued on face value of 5% Notes Conversion of 5% Notes Change in fair value of Level 3 liabilities Balance at December Fair Value Measurement [Table] Fair Value Measurement [Line Items] Scenario [Axis] Other Operating Cost And Expense [Axis] Cumulative Liability Notes Issued Debt Instrument, Convertible, Conversion Price Percentage Of Cash Proceeds From Operation To Repay Convertible Debt Debt Instrument, Term Debt Instrument, Interest Rate During Period Equity Incentive Plans Stock Option Activity [Table] Equity Incentive Plans Stock Option Activity [Line Items] Number of shares, Outstanding Beginning Balance Number of shares, Granted Number of shares, Exercised Number of shares, Forfeited Number of shares, Expired Number of shares, Outstanding Ending Balance Number of shares, Exercisable at December 31, 2017 Weighted - average exercise price, Outstanding Beginning Balance Weighted - average exercise price, Granted Weighted - average exercise price, Exercised Weighted - average exercise price, Forfeited Weighted - average exercise price, Expired Weighted - average exercise price, Outstanding Ending Balance Weighted - average exercise price, Exercisable at December 31, 2017 Weighted - average Contractual Term (in years) Weighted - average Contractual Term, Exercisable at December 31, 2017 (in years) Aggregate Intrinsic Value, Outstanding Ending Balance Aggregate Intrinsic Value, Exercisable at December 31, 2017 Equity Incentive Plans Restricted Stock Activity [Table] Equity Incentive Plans Restricted Stock Activity [Line Items] Class of Stock [Axis] Number of Shares, Outstanding at Begining Balance Number of Shares, Granted Number of Shares, Vested Number of Shares, Forfeited Number of Shares, Outstanding at Ending Balance Weighted Average Grant Date Fair Value, Outstanding at Begining Balance Weighted Average Grant Date Fair Value, Granted Weighted Average Grant Date Fair Value, Vested Weighted Average Grant Date Fair Value, Forfeited Weighted Average Grant Date Fair Value, Outstanding at Ending Balance Statement of Stockholders' Equity [Abstract] Warrants, Outstanding at Beginning Balance Warrants, Issued Warrants, Exercised Warrants, Expired Warrants, Outstanding at Ending Balance Weighted - average exercise price of Warrants, Outstanding at Beginning Balance Weighted - average exercise price of Warrants, Issued Weighted - average exercise price of Warrants, Exercised Weighted - average exercise price of Warrants, Expired Weighted - average exercise price of Warrants, Outstanding at Ending Balance Aggregate Intrinsic Value of Warrants, Outstanding at Beginning Balance Aggregate Intrinsic Value of Warrants, Outstanding at Ending Balance Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Period for Recognition Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Total Milestone-based restricted stock outstanding Stock Issued During Period, Shares, New Issues Share Price Stock Issued During Period, Value, New Issues Proceeds From Issuance Of Common Stock Net Proceeds From Shares New Issues Over-Allotments Common Stock, Shares Authorized Share-based Compensation, Total Common Stock Value Reserved for Future Issuance Commission Percentage Treasury Stock, Shares Treasury Stock, Value Available-for-sale Securities, Equity Securities Purchase Price Notes Payable [Table] Notes Payable [Line Items] Notes payable, Current portion, net Notes payable, Non-current portion, net Total Business Acquisition [Axis] Ariston [Member] Amendment [Axis] Percentage Of Cash Proceeds From Operation To Repay Interest On Convertible Debt Deferred tax assets (liabilities): Net operating loss carryforwards Research and development credit Noncash compensation Other Deferred tax asset, excluding valuation allowance Less valuation allowance Net deferred tax assets Loss before income taxes, as reported in the consolidated statements of operations Computed "expected" tax benefit Increase (decrease) in income taxes resulting from: Expected benefit from state and local taxes Research and development credits Other Impact of change in state tax rates on deferred taxes Stock awards Effects of federal tax reform rate changes Change in the balance of the valuation allowance for deferred tax assets Income Tax Expense (Benefit) Deferred Tax Assets And Liabilities [Table] Deferred Tax Assets And Liabilities [Line Items] Deferred Tax Assets, Valuation Allowance Operating Loss Carryforwards Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent Research and Development Carryforward License Agreement [Table] License Agreement [Line Items] Income Statement Location [Axis] Range [Axis] Related Party [Axis] Upfront Fee Received From Sub License Deferred Revenue Additional Amount Receivable On Achievement Of Pre Specified Milestones Income taxes Stock Issued During Period, Shares, Issued for Services Maximum Potential Payments Payable Royalty payment Effective Percentage Maximum sales for royalty expense Other Research and Development Expense Schedule of Related Party Transactions, by Related Party [Table] Related Party Transaction [Line Items] AOI Communications, L.P [Member] PlacementAgencyAxis [Axis] Sale of Stock, Number of Shares Issued in Transaction Sale of Stock, Price Per Share Sale of Stock, Consideration Received on Transaction Accounts Payable Costs and Expenses, Related Party Prepaid Research And Development Average Annual Rental Payments Payment due by period, Contractual obligations, Operating leases, Less than 1 year Payment due by period, Contractual obligations, Operating leases, 1-3 years Payment due by period, Contractual obligations, Operating leases, 3-5 years Payment due by period, Contractual obligations, Operating leases, More than 5 years Payment due by period, Contractual obligations, Operating leases, Total Placement Agency Agreement [Axis] Operating Leases, Rent Expense, Net, Total Operating Leases, Future Minimum Payments Due, Total License revenue Total costs and expenses Net loss Basic and diluted net loss per common share Reflects potential milestone payments to be received upon achievement of pre-specified milestone. amendement of business amendment domain The yearly payments due under the lease entered into in connection with the possession of the office space. Reflects the description of business of the entity. The change in fair value of notes payable during the period. Reflects agreemnet collaboration of the company Represents the value of common stock reserved for future issuance. Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Fair value disclosures related to financial assets (as defined) and financial liabilities (as defined) contained in the entity's balance sheet. Disclosures contained in this table include the changes in level 3 instruments. Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Amount of interest recognized during the period, arising from liabilities measured at fair value on a recurring basis using unobservable inputs (level 3). Disclosure related to policy for impairment of tangible and intangible asset including goodwill. represents incentives plan of 2012 Number of shares issued during the period upon the conversion of convertible securities. License Agreement [Abstract] The entire disclosure for research, development, and License Agreement activities, including contracts and arrangements to be performed for others and with federal government. Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Disclosure of accounting policy for reporting when there is a substantial doubt about an entity's ability to continue as a going concern for a reasonable period of time (generally a year from the balance sheet date). Disclose: (a) pertinent conditions and events giving rise to the assessment of substantial doubt about the entity's ability to continue as a going concern for a reasonable period of time, (b) the possible effects of such conditions and events, (c) management's evaluation of the significance of those conditions and events and any mitigating factors, (d) possible discontinuance of operations, (e) management's plans (including relevant prospective financial information), and (f) information about the recoverability or classification of recorded asset amounts or the amounts or classification of liabilities. If management's plans alleviate the substantial doubt about the entity's ability to continue as a going concern, disclosure of the principal conditions and events that initially raised the substa Represents the maximum potential milestone payments upon the achievement of specific clinical regulatory and commercial milestone events. Represents the maximum sales for royalty expense. Represents the net proceeds from issuance of common stock over-allotments during the period. The aggregate compensation expense related to the grants of stock options and restricted stock that is attributable to general and administrative expenses during the reporting period. The aggregate compensation expense related to the grants of stock options and restricted stock that is attributable to research and development expenses during the reporting period. represents restricted shares outstanding issued to non-employees Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Represents the aggregation and reporting of combined amounts of individually immaterial business combinations that were completed during the period. Amount of cash outflow (inflow) through acquisition (sale) of short-term held-to-maturity securities. Reflects level of percentage of net product cash flow received from the exploitation or commercialization of certain product candidates to repay certain convertible debt. Reflects level of percentage of net product cash flow received from the exploitation or commercialization of certain product candidates to repay certain convertible debt. Disclosure about period anticipated sufficient to fund operating cash flow. Represents Placement Agency Agreement Represents Placement Agency Agreement. Represents the amount of prepaid manufacturing. Sum of the amounts paid in advance for capitalized costs that will be expensed with Research and development. The cash inflow associated with the maturities of held-to-maturity securities. Price paid per share for the purchase of the number of participating preferred shares. Amount of noncash expense included in APIC to obtain financing associated with the related debt instruments. Represents the Royalty payment Effective Percentage. Tabular disclosure of Share based compensation expense during the period. Tabular disclosure for warrants activity. Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Schedule reflecting the organisation and summary of significant accounting policies. Number of shares issued for cash. Represents the number of shares of stock issued during the period due to the exercise of warrants. Represent stock issued during period shares exercise of warrants cash less Number of new stock issued during the period. Represents the value of stock issued during the period due to the exercise of warrants. Represent stock issued during period value exercise of warrants cash less Equity impact of the value of new stock issued during the period. Includes shares issued in an market public offering or a secondary public offering. Values of share issued for cash. Represents amount received for sub license. Reflects the aggregate intrinsic value of warrants outstanding. Reflects the number of warrants exercised during the period. Reflects the weighted average exercise price of warrants Exercised. Reflects the number of warrants expired during the period. Reflects the weighted average exercise price of warrants Expired. Reflects the number of warrants issued during the period. Reflects the weighted average exercise price of warrants outstanding. Assets, Current Assets [Default Label] Liabilities, Current Liabilities Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest Liabilities and Equity Research and Development Expense Non Cash Compensation General and Administrative Expenses General and Administrative Expense Operating Income (Loss) Interest Income, Other Other Income Nonoperating Income (Expense) Shares, Outstanding Stock Issued During Period, Shares, Restricted Stock Award, Forfeited Change In Fair Value Of Notes Payable Increase (Decrease) in Restricted Cash Increase (Decrease) in Other Current Assets Increase (Decrease) in Accrued Interest Receivable, Net Increase (Decrease) in Other Noncurrent Assets Net Cash Provided by (Used in) Operating Activities, Continuing Operations Payments to Acquire Property, Plant, and Equipment Payments To Acquire Held To Maturity Securities Short Term Net Cash Provided by (Used in) Investing Activities, Continuing Operations Payments of Financing Costs Net Cash Provided by (Used in) Financing Activities, Continuing Operations Cash and Cash Equivalents, Period Increase (Decrease) Fair Value, Measurement with Unobservable Inputs Reconciliations, Recurring Basis, Liability Value Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Class of Warrant or Right, Outstanding Warrant Or Right Exercised Warrant Or Right Expired Warrant Or Right Outstanding Weighted Average Exercise Price Warrant Or Right Aggregate Intrinsic Value Notes Payable Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits Deferred Tax Assets, Gross Deferred Tax Assets, Net of Valuation Allowance Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount Effective Income Tax Rate Reconciliation, Other Adjustments, Amount Placement Agency Agreement [Axis] [Default Label] Clearing Fees Revenue Net Income (Loss) Attributable to Parent